Yahoo Finance Lucid Diagnostics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags
Lucid Diagnostics (NASDAQ:LUCD) First Quarter 2023 Results
Key Financial Results
Net loss: US$16.2m (loss widened by 32% from 1Q 2022).
US$0.40 loss per share (further deteriorated from US$0.35 loss in 1Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Lucid Diagnostics Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 95%. Earnings per share (EPS) missed analyst estimates by 19%.
Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 5 warning signs for Lucid Diagnostics (2 are a bit unpleasant) you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
